NEW YORK ( TheStreet) -- ViroPharma (Nasdaq: VPHM) hit a new 52-week high Monday as it is currently trading at $31.45, above its previous 52-week high of $31 with 159,260 shares traded as of 9:45 a.m. ET. Average volume has been 1.2 million shares over the past 30 days. ViroPharma has a market cap of $2.08 billion and is part of the health care sector and drugs industry. Shares are up 11.8% year to date as of the close of trading on Friday. ViroPharma Incorporated, together with its subsidiaries, engages in the development and commercialization of therapeutic products that address serious diseases in the United States and internationally. The company has a P/E ratio of 20.9, above the average drugs industry P/E ratio of 20.2 and above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates ViroPharma as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full ViroPharma Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.